Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

1. Wu, Y.-L.
2. Cheng, Y.
3. Zhou, X.
4. Lee, K.H.
5. Nakagawa, K.
6. Niho, S.
7. Tsuji, F.
8. Linke, R.
9. Rosell, R.
10. Corral, J.
11. Migliorino, M.R.
12. Pluzanski, A.
13. Sbar, E.I.
14. Wang, T.
15. White, J.L.
16. Nadanaciva, S.
17. Sandin, R.
18. Mok, T.S.